Molecular Partners AG announced the presentation of new preclinical data from the company's Radio DARPin Therapy Platform at the 12th International Symposium on Targeted Alpha Therapy (TAT 12) in Cape Town, South Africa on February 28, 2023. The platform represents a unique and innovative delivery system for radioactive payloads to solid tumors, an approach with proven potential but with technological limitations that DARPins may address. The presented data demonstrate Molecular Partners' ability to engineer the surface of DARPin-based radiotherapeutics to dramatically reduce its accumulation in the kidney, a historical challenge with small protein-based delivery vectors.

In preclinical models, the surface engineering did not affect tumor uptake or uptake in other healthy organs and combination with another kidney reduction strategy provided a cumulative benefit. These results will be presented at TAT12 in a poster, the details of which can be found below. The poster will be made available on Molecular Partners website, after the presentation.Poster: “DARPins as Powerful Targeting Agents for Radioligand Therapeutics” Number: 33, Timing:February 28, 2023, Presenter:Daniel Steiner, Ph.D., Senior Vice President of Oncology Research.